Afinitor Disperz and Nourianz
Determining the interaction of Afinitor Disperz and Nourianz and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.MONITOR: Coadministration with inhibitors of CYP450 3A4 and/or P-glycoprotein may increase the blood concentrations of everolimus following oral administration. Everolimus is a substrate of both the CYP450 3A4 isoenzyme and P-glycoprotein drug efflux transporter, thus their inhibition in the intestine can enhance the absorption of everolimus. MANAGEMENT: The possibility of prolonged and/or increased pharmacologic effects of everolimus therapy should be considered during coadministration with CYP450 3A4 and/or P-glycoprotein inhibitors, including adverse effects such as pneumonitis, stomatitis, infection, dyspnea, diarrhea, anemia, leucopenia, thrombocytopenia, hyperglycemia, and hyperlipidemia. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy. References "Product Information. Afinitor (everolimus)." Novartis Pharmaceuticals, East Hanover, NJ.
Professional:MONITOR: Coadministration with inhibitors of CYP450 3A4 and/or P-glycoprotein may increase the blood concentrations of everolimus following oral administration. Everolimus is a substrate of both the CYP450 3A4 isoenzyme and P-glycoprotein drug efflux transporter, thus their inhibition in the intestine can enhance the absorption of everolimus.
MANAGEMENT: The possibility of prolonged and/or increased pharmacologic effects of everolimus therapy should be considered during coadministration with CYP450 3A4 and/or P-glycoprotein inhibitors, including adverse effects such as pneumonitis, stomatitis, infection, dyspnea, diarrhea, anemia, leucopenia, thrombocytopenia, hyperglycemia, and hyperlipidemia. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy.
- "Product Information. Afinitor (everolimus)." Novartis Pharmaceuticals, East Hanover, NJ.
Generic Name: everolimus
Brand name: Afinitor, Afinitor Disperz, Zortress
Synonyms: n.a.
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Afinitor Disperz-Nov-Onxol
- Afinitor Disperz-Novacort
- Afinitor Disperz-Novaferrum
- Afinitor Disperz-NovaFerrum 50
- Afinitor Disperz-NovaFerrum Pediatric Drops
- Afinitor Disperz-NovaFerrum Pediatric Multivitamins with Iron
- Nourianz-Afirmelle
- Nourianz-Aflaxen
- Nourianz-Aflexeryl-MC
- Nourianz-Afluria
- Nourianz-Afluria 2015-2016 Formula
- Nourianz-Afluria injection